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Abstract
Aim Clinical trials have demonstrated the efficacy of the
tetravalent human papillomavirus (HPV) vaccination in the
prevention of cervical cancer and genital warts associated
with HPV types 6, 11, 16 and 18. We used an empirically
calibrated Markov cohort model of the natural history of
HPV to assess the cost-effectiveness of the vaccine
administered to 12-year-old girls alongside existing cervical
screening programmes in Germany.
Subjects and methods The model estimated cervical cancer
(CC), cervical intraepithelial neoplasia (CIN) and genital
wart lifetime risks and total lifetime health care costs, life
years gained and quality-adjusted life years (QALY)
gained. The analysis was conducted from the perspective
of the German health care payer.
Results In the base case (considering a lifetime duration of
protection and 100% efficacy) it was estimated that 2,835
cervical cancer cases and 679 deaths could be prevented
among a cohort of 400,000, at an incremental cost per
QALY gained of 10,530 €. A total of 120 girls needed to be
vaccinated to prevent 1 case of CC. Cost-effectiveness is
sensitive to a duration of protection of less than 20 years
and to the discount rate for costs and benefits.
Conclusion A policy of vaccinating adolescent girls has
been recommended by the German Standing Committee on
Vaccinations. This study has demonstrated that such a
policy is cost-effective based on thresholds of cost-
effectiveness that apply in Germany.
Keywords Human papillomavirus (HPV) vaccine .
Cost-effectiveness . Germany
Introduction
Cervical cancer is among the most common female cancers
in many countries. In Germany, there are an estimated
6,190 new cases every year and about 1,660 deaths (Robert
Koch-Institut 2008). Epidemiological research conducted
during the last 15–20 years has provided overwhelming
evidence for the aetiological role for infection with certain
types of human papillomavirus (HPV) as the primary cause
of cervical cancer. This virus is also responsible of other
anogenital cancers (vulva, vaginal, anus, penile), head and
neck cancers and genital warts (Munoz et al. 2006).
In Germany, cervical cancer is one of the target cancers
covered by the statutory early detection cancer screening
programme which was introduced in West Germany in
1971 and expanded to the eastern part of the country in
1991 (Schenck and von Karsa 2000). Women covered by
statutory health insurance (over 90% of the population) are
eligible to receive an annual cervical examination including
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a Papanicolaou (Pap) smear beginning at the age of 20 years
(Schenck and von Karsa 2000). Since the programme is
based on opportunistic screening, the attendance rates have
been low and only reached about 50% of females by the
end of the 1990s (Schenck and von Karsa 2000). Therefore,
screening alone cannot be expected to prevent all cases of
cervical cancer.
The development of a prophylactic vaccine against HPV
is a major breakthrough in the prevention of invasive
cervical cancer. In 2006, the first prophylactic tetravalent
HPV recombinant vaccine (HPV types 6,11,16,18) was
granted marketing authorisation in the European Union.
This tetravalent vaccine is indicated for the prevention of
high-grade cervical dysplasia (CIN 2/3), cervical carcino-
ma, high-grade vulvar dysplastic lesions (VIN 2/3) and
external genital warts causally related to HPV types 6, 11,
16 and 18. In 2007, a bivalent vaccine (HPV types 16 and
18), indicated for the prevention of CIN grades 2 and 3 and
cervical cancer causally related to HPV types 16 and 18,
was approved for use by the European Medicines Agency.
Both vaccines have been shown to be highly effective in
large phase III clinical trials (FUTURE II Study Group
2007; Paavonen et al. 2007).
The objective of this study was to conduct a cost-
effectiveness analysis of a tetravalent HPV recombinant
vaccine in 12-year-old girls alongside the existing cervical
cancer screening programme in Germany.
Study methodology
Model structure
A published and validated US Markov model of the natural
history of HPV infection and cervical cancer (Myers et al.
2000) has recently been adapted to the UK (Kulasingam et al.
2008). We adapted this model to a German health care
context to provide the basis of the cost-effectiveness
analysis.
The Markov model follows a cohort of girls aged 12 up
to age 85 through different health states covering HPV
infection, cervical intraepithelial neoplasia (CIN), cervical
cancer and genital warts. Movement between the health
states is based on annual transition probabilities. Each year,
an age-specific risk of acquiring an oncogenic HPV
infection is applied to women in the cohort. Then, women
infected with HPV can, with varying levels of probability,
return to a ‘well’ state, suffer a persistent infection, progress
to CIN 1, or in some cases, progress directly to CIN 2.
Women who develop CIN 1, CIN 2 or CIN 3 are at risk of
developing cervical cancer. The severity of cervical cancer
is staged according to the Fédération Internationale de
Gynécologie et d’Obstétrique (FIGO) classification system
(FIGO I–IV). Each year women face an age-specific risk of
dying from other causes.
Each year there is a risk of developing genital warts
which varies depending on the woman’s age. It is assumed
that the genital warts will be cured within the year and the
woman will return to a normal health state. Hence, the
occurrence of genital warts is not associated with a disease
state, but is rather considered as a transitory event in the
model.
To be representative of the German health care context,
the Markov model was adapted in three main ways.
Firstly, the model was structurally adapted to reflect the
screening and treatment pathways in Germany. In the
USA and the majority of European countries, cytology
screening results, using Pap smears, are classified accord-
ing to the Bethesda system which reports LSIL (low-grade
squamous intraepithelial lesion also known as CIN 1) and
HSIL (high-grade squamous intraepithelial lesion also
known as CIN 2/3). In Germany, the PAP (Munich II)
system is employed (Schenck and Soost 1995). Therefore,
the parameters in the model were adapted to correspond
with the PAP system.
Secondly, the model was populated with German
epidemiological and economic data derived from various
sources that are detailed below. Thirdly, the model was
calibrated to fit the age-specific cancer incidence curve for
a screened population (Krebsregister 2003) and the results
from a published decision-analytic model on the natural
history of cervical cancer developed specifically for
Germany (Siebert et al. 2006).
The model was programmed using the software TreeAge
Pro (TreeAge Software Inc., Williamstown, MA, USA).
Vaccination strategy
We compared a routine vaccination programme of 12-year-
old girls with a tetravalent HPV vaccine to the current
cervical cancer screening programme. In the base case
analysis it was assumed that vaccination coverage would be
80% of the eligible population and that screening practices
would be unaffected by vaccination status.
Natural history parameters
Natural history parameters for progression and regression
of disease used in the UK model were assumed to apply
across Europe; hence, transition probabilities data were first
extracted from the UK model (Kulasingam et al. 2008)
(Table 1). Then, age-specific rates of HPV infection applied
to the model were slightly modified to fit the age-specific
cervical cancer incidence curve as part of the calibration
process (Krebsregister 2003). The rates were higher for the
age 20 and 21, which is consistent with the fact that
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acquisition of HPV occurs very quickly after the onset of
sexual activity. In addition, using the same approach as
others (Siebert et al. 2006), we varied probability of
symptoms for FIGO stages to obtain a distribution of
cervical cancer stages similar to that of an unscreened
population.
Five-year survival by cancer stage inputs were derived
from Siebert et al. (2004). Age-specific hysterectomy
proportions in the German general population (Siebert et al.
2004) and age-specific incidence of genital warts in women
were additional inputs in the model (Hillemanns et al. 2008).
The mortality rate of women in the general population comes
Table 1 Natural history parameters used in the model
Parameter Age Transition
probability
Time
period
Source
Normal
Normal to HPV-infected state 14–18 0.020–0.080 12 months Calibrated from Canfell et al. (2004)
19–29 0.160–0.250
30–39 0.025–0.045
50+ 0.0095
HPV infection
HPV infection to CIN 1 or CIN 2 All 0.0959 12 months Canfell et al. (2004)
Proportion of HSIL that are CIN 2 All 0.1350 –
CIN
CIN 1 to well 12–24 0.7000 18 months Calibrated from Canfell et al. (2004)
and Myers et al. (2000)25–39 0.5000
40–49 0.2700
50+ 0.1000
CIN 1 to CIN 2 16–34 0.0297 12 months Canfell et al. (2004)
35+ 0.1485
CIN 1 to CIN 3 All 0.0301 12 months
CIN 1 to HPV-infected state 16–34 0.2248 12 months
35+ 0.1124
Proportion CIN 1 regressing
directly to well
All 0.90 –
CIN 2 to CIN 3 16–34 0.0389 12 months
35–44 0.0797
45+ 0.1062
CIN 2 to CIN 1 All 0.2430 12 months
CIN 2 to well or HPV-infected state All 0.1901 12 months
Proportion CIN 2 regressing
directly to well
All 0.90 –
CIN 3 to CIN 1 All 0.0000 12 months
CIN 3 to CIN 2 All 0.0135 12 months
CIN 3 to well or HPV-infected state 16–44 0.0135 12 months
45+ 0.0100
Proportion CIN 3 regressing
directly to well
All 0.50 –
CIN 3 to invasive cervical cancer All 0.013 12 months Canfell et al. (2004)
Cervical cancer
Progression rates
FIGO stage I 0.90 48 months Myers et al. (2000)
FIGO stage II 0.90 36 months
FIGO stage III 0.90 15 months
FIGO stage IV 0.90 12 months
Probability of symptoms
FIGO stage I 0.11 12 months Calibrated from Canfell et al. (2004)
and Myers et al. (2000)FIGO stage II 0.23
FIGO stage III 0.60
FIGO stage IV 0.80
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from official statistics (Federal Statistical Office Germany
Statistics 2004).
German screening programme
In Germany, cervical screening is recommended from age
20 (Schenck and von Karsa 2000), with a follow-up of a
repeat screen each year if the Pap result is normal (Siebert
et al. 2006; Anttila and Jordan 2004; Bollmann et al. 2005).
The model was structurally adapted to reflect the current
screening pathways in Germany in the case of abnormal
results, although substantial differences exist among gener-
al physicians in terms of management (Sheriff et al. 2007).
In the model, women presenting with LSIL (PAP III D)
were assumed to undergo a repeat Pap smear every
3 months for 1 year, with colposcopy and biopsy if the
lesion remains persistent, while those with HSIL (PAP IV)
were assumed to undergo repeat cytology, colposcopy and
biopsy with immediate effect (Siebert et al. 2006; Bollmann
et al. 2005). Women who present with an atypical squamous
cell of undetermined significance (ASC-US) result undergo a
repeat Pap smear within 6 months, with colposcopy and
biopsy if the lesion remains persistent (Siebert et al. 2006;
Anttila and Jordan 2004; Bollmann et al. 2005).
The screening coverage rate was age specific, ranging
from 17.7% for the age group 65–69 years up to 52.6% for
the age group 45–54 years (European Commission 2002).
Characteristics of the screening tests are presented in
Table 2. Treatment of CIN was assumed to be 100%
effective, resulting in the patient returning to a HPV-
infected state without CIN; 90% of women with CIN 1 and
all women with CIN 2/3 were assumed to be treated.
Vaccine efficacy
Based on recently published randomised clinical trials
(Garland et al. 2007; Lacey 2008; FUTURE II Study
Group 2007), the vaccine was assumed to be 100%
effective against HPV types 6, 11, 16 and 18. In the model,
it was estimated that these four types are responsible for
35% of CIN 1 cases. In addition, 55% of CIN 2/3 cases and
70% of cancer cases are caused by HPV types 16 and 18,
and 90% of cases of genital warts are caused by HPV types
6 and 11 (Clifford et al. 2003, 2005; von Krogh 2001).
A high sustained efficacy against HPV 16/18-related
CIN 2/3 has been demonstrated for the tetravalent vaccine
in large phase II/III trials with follow-up periods (after start
of vaccination) up to 5 years in phase II and up to 4 years in
phase III (Lacey 2008). Moreover, a three-dose regimen of
the tetravalent HPV vaccine induced high efficacy and
stable anti-HPV levels for at least 5 years in a recent study,
suggesting that the efficacy of this vaccine will be long
lasting (Olsson et al. 2007). Therefore, the base case
assumption was that duration of protection would be
lifelong without the need for a booster, similar to the
approach adopted in other cost-effectiveness analyses
(Brisson et al. 2007b; Bergeron et al. 2008; Dasbach et al.
2008; Chesson et al. 2008).
Cross-protection effect of the vaccine was not considered
in our analysis, although recent clinical cross-protection
efficacy has been demonstrated against ten additional
oncogenic human papillomavirus types (Brown 2007).
Costs
Unit costs are presented in Table 3. The analysis has been
carried out from the German health care payer perspective.
Medical resource use associated with screening and
subsequent disease management, 5-year costs for treating
cervical cancer by FIGO stage as well as costs for treatment
of genital warts were derived from three German studies
(Petry et al. 2008; Siebert et al. 2004; Hillemanns et al.
2008).
The cost of one 0.5-ml dose of a tetravalent HPV
vaccine used in the model is 143.8 € and as three doses are
required for effective disease prophylaxis the total cost per
person vaccinated is 439.8 €. The unit cost of administra-
tion by a general practitioner (GP) is estimated to be 6.5 €
per vaccination representing the mean fee for a GP visit for
single vaccination administration across German federal
states and insurance providers.
Utilities and discount rates
Utility estimates, used to calculate quality-adjusted life
years (QALYs), are presented in Table 4. In the absence of
European-specific data, these estimates were derived from a
US time trade-off study conducted in 150 healthy female
Table 2 Sensitivity and specificity of Pap test, colposcopy and biopsy
Value Source
Sensitivity of a Pap test for detecting CIN 1/2 0.435 Petry et al. (2003)
Sensitivity of a Pap test for detecting CIN 3/cervical cancer 0.64 Karnon et al. (2004)
Specificity of a Pap test 0.95 Siebert et al. (2006)
Sensitivity of colposcopy with biopsy 0.9 Canfell et al. (2004) and Mitchell et al. (1998)
Specificity of colposcopy with biopsy 1 Karnon et al. (2004)
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volunteers (Myers et al. 2004). The expected time consid-
ered in each state of health was the same as that in a UK
analysis using the same core model (Kulasingam et al.
2008). The utility for those surviving cervical cancer was
assumed to be 1.0.
In the absence of specific recommended discount rates
for prevention technologies, the base case rates applied
were those recommended in Dutch pharmacoeconomic
guidelines (Dutch Health Care Insurance Board 2005).
Discount rates of 4% for costs and 1.5% per annum for
future health benefits (LYGs and QALYs) were applied in
the base case. Given the high uncertainty in the appropriate
discount rate a range from 0 to 5% for costs and benefits
was also applied in sensitivity analysis.
Outputs and analyses
The model was used to produce estimates of cervical
cancer, CIN and genital wart lifetime risks, total lifetime
costs and incremental cost-effectiveness ratios (ICERs): the
incremental cost per life year gained (LYG), and incremen-
tal cost per QALY gained.
The number needed to vaccinate (NNV) to prevent cases
of cervical cancer is a useful measure of vaccine effective-
ness (Brisson et al. 2007a). Using the natural history model,
the NNV with the tetravalent HPV vaccine in Germany was
estimated. NNV was defined as the number of 12-year-old
girls that are needed to be vaccinated to prevent an HPV-
related event during their lifetime, calculated as follows:
NNV = 1/ARR, with ARR representing attributable risk
reduction (Brisson et al. 2007a).
One-way sensitivity analysis was undertaken to explore
the impact on cost-effectiveness of varying a range of key
parameters for duration of vaccine protection, vaccine and
administration costs, Pap sensitivity, utilities, discount rates
and screening coverage. The impact on cost-effectiveness
of a scenario of administering a booster vaccine (one dose)
to 50% of females originally vaccinated was also explored.
Results
Model validation
The model was calibrated to predict a lifetime risk of
cervical cancer of 3.1% and a lifetime risk of death due to
cervical cancer of 1.08% in Germany in the absence of
screening. Moreover the model predicts the following
distribution for FIGO stage at diagnosis (before screening
implementation): FIGO I: 38.4%, FIGO II: 30.3%, FIGO
III–IV: 31.3%. These predictions are consistent with
findings from Siebert et al. (2006).
As shown in Fig. 1, the model was also calibrated so that
the predicted age-specific annual incidence of invasive
cervical cancer in the German screened population was
similar to the observed data for Germany (Krebsregister
2003), demonstrating the validity of the model adaptations
for the German context.
Table 4 Utility values used in the model
Health status Utility value Time period
Routine screening Pap smear 0.98 1 month
ASC-US diagnosis from Pap smear 0.94 2 months
LSIL/HSIL diagnosis from Pap smear 0.91 2 months
Genital warts 0.91 85 days
CIN 1 0.91 2 months with 10 months follow-up
CIN 2/3 0.87 2 months
FIGO I 0.76 5 years
FIGO II–IV 0.67 5 years
Source: Myers et al. (2004) and Kulasingam et al. (2008)
Table 3 Costs of detecting and treating precancerous lesions and
cervical cancer
Parameter Cost (€) Source
Pap smear 24.8 a
Colposcopy 23.6
Biopsy 106
Treatment of CIN 1/CIN 2 336 Based on Petry et al. (2008)b
Treatment of CIN 3 1,498
Treatment of FIGO I 7,523 Siebert et al. (2004)
Treatment of FIGO II 12,983
Treatment of FIGO III 18,315
Treatment of FIGO IV 17,152
Treatment of genital wart 550 Hillemanns et al. (2008)
a Outpatient costs come from Kassenärztliche Bundesvereinigung:
Einheitlicher Bewertungsmaßstab für ärztliche Leistungen. http://
www.kbv.de/ebm2000plus/EBMGesamt.htm. Accessed 22 Nov 2006
b This represents the mean cost of interventional procedures in Petry et
al. (2008), assuming that PAP III and PAP III B were CIN 1 or CIN 2
and that PAP IV were CIN 3
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Health benefits
Under base case assumptions (vaccination coverage rate of
80% and lifelong duration of protection) for a birth cohort of
about 400,000 females in Germany, the model estimates that
2,835 cervical cancer cases and 679 deaths could be avoided.
In addition, 7,776, 5,921 and 9,962 cases of detected CIN 1,
2 and 3 cases, respectively, and 28,310 cases of genital warts
could be avoided (Table 5).
Base case cost-effectiveness analysis
The incremental cost-effectiveness of a screening plus
vaccination programme from a health care payer perspec-
tive in Germany versus screening alone was estimated to be
15,684 € per LYG and 10,530 € per QALY gained (Table 6).
These ratios are well below the incremental cost-effective-
ness threshold relevant to Germany of 50,000 € per QALY.
Therefore, a vaccination programme with a tetravalent HPV
vaccine alongside the current screening programme can be
considered as a cost-effective strategy.
The cost per cervical cancer avoided (undiscounted) is
estimated at 24,519 € and the cost per event avoided
(cervical cancer, CIN or female genital warts) at 1,253 €.
Sensitivity analyses
The base case assumes lifetime duration of protection for
vaccination. Incremental cost-effectiveness was sensitive to
durations of protection of less than 20 years, but not for
longer durations up to lifetime. Furthermore, a scenario in
which booster vaccination is provided (after 10 years) for
50% of females originally vaccinated in order to ensure
lifetime protection produced an increased cost-effectiveness
ratio compared to the base case, primarily due to the impact
of the increased cost of providing a booster (Table 7).
Cost-effectiveness was very sensitive to the discount rate
used, with higher joint discount rates for costs and benefits
resulting in higher cost-effectiveness ratios (Table 7). If
costs and health benefits were jointly discounted at 3%,
which is similar to the rate recommended in several
economic evaluation guidelines across Europe, the incre-
0,0
5,0
10,0
15,0
20,0
25,0
30,0
35,0
15
-
19
20
-
24
25
-
29
30
-
34
35
-
39
40
-
44
45
-
49
50
-
54
55
-
59
60
-
64
65
-
69
70
-
74
75
-
79
80
-
84
age group
ce
rv
ic
al
 c
an
ce
r i
nc
id
en
ce
 / 
10
0 
00
0
simulated
observed 
Fig. 1 Simulated and observed
cervical cancer incidence for the
screened population
Table 5 Estimated number of cases avoided per 400,000 cohorta
Strategy Cervical
cancer
Deaths from
cervical cancer
CIN 3
detected
CIN 2
detected
CIN 1
detected
Genital
warts
Screening only 4,783 1,146 21,514 12,868 23,455 40,299
Screening and vaccination 1,948 468 11,552 6,947 15,679 11,989
Cases avoided 2,835 679 9,962 5,921 7,776 28,310
a Assuming 80% coverage rate, lifetime duration of protection
82 J Public Health (2009) 17:77–86
mental cost-effectiveness increased to 18,636 € per QALY
gained. If the discount rate is 5% for both costs and
benefits, the ICER increased to 42,493 € per QALY gained.
In contrast, with zero discounting of costs and benefits the
ICER was less than 3,049 € per QALY gained.
The cost-effectiveness ratio was insensitive to changes in
treatment costs, efficacy, utility parameters and application
of a zero disutility for a routine Pap smear test (Table 7).
Varying the sensitivity of the Pap smear for detection of
CIN 1/2 or CIN 3 had a small impact on the cost-
effectiveness ratio.
The impact of different screening strategies associated or
not with vaccination was also considered. In our base case
analysis, 2,835 incremental cases of cervical cancer and
679 incremental deaths could be avoided thanks to the
introduction of the HPV vaccination compared to the
current screening programme alone. If the screening
coverage rate was increased by 20% without HPV
vaccination, only 717 incremental cases of cervical cancer
and 231 incremental deaths from cervical cancer could be
avoided. If the screening coverage rate decreased by 20%
after the vaccination programme implementation, 2,442
additional cancer cases and 541 additional deaths could be
avoided. In this context, introducing HPV vaccination in
association with a screening programme (less or as efficient
as the current one) appeared to be more efficient than only
improving the existing screening intervention.
Number needed to vaccinate
The NNV to prevent one case of cervical cancer was
estimated to be 120 based on a birth cohort of 400,000 12-
year-old girls. For this we assumed a vaccination coverage
rate of 100%. For CIN 1, CIN 2 and CIN 3 related to HPV
the NNV to prevent one case was estimated by the model to
be 45, 55 and 33, respectively, and the NNV for genital
wart was estimated to be 11. Six girls need to be vaccinated
to prevent one HPV-related clinical event.
Table 6 Incremental cost-effectiveness from a German health care payer perspective
Costs (€) Mean LYGs Incremental cost/LYG (€) QALYs Incremental cost/QALY (€)
Screening only 314.1 42.55 – 42.4989 –
Screening + vaccination 612.2 42.569 15,684 42.5272 10,530
Table 7 Sensitivity analysis
for key parameters
a One dose of booster given
10 years after the three doses in
50% of the cohort. No efficacy
is assumed after 10 years for
the 50% of non-vaccinated
girls
Incremental cost/LYG (€) Incremental cost/QALY (€)
Base case 15,684 10,530
Duration of protection
Lifelong achieved with a boostera 24,943 17,034
20 years 28,991 19,445
Vaccine efficacy
90% efficacy 16,872 11,681
Vaccine cost
-20% 12,053 8,092
20% 19,321 12,972
Treatment cost (CIN and cancer)
-20% 16,311 10,951
20% 15,063 10,113
Pap sensitivity for detection of CIN 1
50% 16,394 10,731
Pap sensitivity for detection of CIN 2/3
55% 11,400 8,211
75% 23,069 12,972
Utilities
-50% duration NA 11,037
+50% duration NA 9,313
Discount rate for costs/benefits
0%/0% 4,138 3,049
3%/3% 30,258 18,636
5%/5% 81,632 42,493
5%/0% 7,386 5,442
Exclusion of genital warts 16,689 11,658
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Discussion
Although previous studies have assessed the cost-effective-
ness of HPV vaccination in other European countries
(Bergeron et al. 2008; Dasbach et al. 2008), this is the first
analysis conducted on HPV vaccination Germany. Until
now, cost-effectiveness studies specific to Germany have
focussed on the cost-effectiveness of several screening
strategies (Mittendorf et al. 2003; Siebert et al. 2004;
Sheriff et al. 2007). Based on a vaccination coverage rate of
80%, the use of a quadrivalent vaccine alongside the
current national cervical cancer screening programme was
found to be a cost-effective public health initiative
compared to screening alone, with an incremental cost per
QALY gained and LYG gained that was well within the
accepted threshold for cost-effectiveness in Germany
(Siebert et al. 2004). In terms of health benefits the model
has shown that the introduction of a tetravalent vaccine has
the potential to substantially reduce the public health
burden associated with cervical cancer, with an estimated
reduction of nearly 3,000 cases and 700 deaths for a cohort
of 400,000 females vaccinated at the age of 12. Sensitivity
analysis has shown that the results are relatively insensitive
to varying the base case parameters for screening and
vaccine coverage rates, natural history, Pap smear sensitiv-
ity, cost and utility variables. The only variable that results
in cost-effectiveness ratios above 50,000 € per QALY
gained was if a very short duration of protection is
assumed. An incremental cost per LYG above 50,000 €
was associated with applying relatively high rates of
discounting (5%) for both costs and health outcomes. There
is much debate regarding the value of the discount rate
used, particularly when evaluating public health pro-
grammes such as vaccination. Discounting may undervalue
preventive interventions for which the benefits appear long
after the costs have been paid, such as HPV vaccination
programmes (Crott 2007).
We note some limitations in our analysis. Firstly, utility
estimates, required to calculate cost per QALY, were
derived from a study conducted in the USA (Myers et al.
2004). To our knowledge, no specific data for Germany, or
any other European countries, have been published so far.
In addition, our utility estimates are conservative compared
with estimates used in other published cost-effectiveness
analyses (Brisson et al. 2007b; Goldie et al. 2004).
Secondly, we considered a compliance of 100% for the
three doses of the vaccines. It may happen that some girls
received only two doses instead of three, although it is
difficult to make an assumption on this. Lastly, previous
German economic studies suggested that HPV testing would
improve screening performance (Sheriff et al. 2007). How-
ever, we decided not to include HPV testing in our analysis
as HPV testing is not standard practice in Germany.
Our analysis can be considered as conservative in several
aspects. Firstly, as we used a Markov model it was not
possible to include the herd immunity effects of the
vaccination programme. For instance, it is not possible to
assess the indirect benefits of the vaccine by avoiding HPV-
related diseases in males. To measure these additional
benefits, a dynamic transmission model would be necessary.
A number of dynamic models exist (Dasbach et al. 2006),
among which two have examined the cost-effectiveness of
quadrivalent HPV (6/11/16/18) vaccination strategies in
Europe (Jit et al. 2008; Dasbach et al. 2008). Secondly, our
model did not cover the cross-protection effect of the vaccine
and the impact of the tetravalent HPV vaccine on the
prevention of other cancers, in particular vaginal and vulval
cancers or laryngeal papillomas, related to HPV types 6, 11,
16 and 18. A recent US cost-effectiveness analysis showed
that the inclusion of potential additional benefits of prevent-
ing anal, vaginal, vulvar and oropharyngeal cancers could
decrease the cost per QALY by at least 20% (Chesson et al.
2008). Furthermore, indirect costs of lost productivity were
not included, which would potentially further improve cost-
effectiveness from a societal perspective.
Economic analyses such as ours can help to provide
information for public health policy and reimbursement
decisions on an HPV vaccination programme. In the case of
HPV vaccines, it can also highlight the difference between
a bivalent and a quadrivalent vaccine. The types 6 and 11
included in the quadrivalent vaccine are responsible for
90% of genital warts and for around 10% of CIN 1. In our
model, the cost-effectiveness ratio is increased by 10%
when benefits of the vaccine on genital warts are removed.
This result is modest as compared to findings from other
countries which can be the results of not having an HPV
type specific model. A Canadian cost-effectiveness study
showed that the cost-effectiveness ratio of vaccinating a
cohort of 12-year-old girls with the quadrivalent (HPV 6/
11/16/18) and with the bivalent (HPV 16/18) vaccine would
be of Canadian $20,512 and 31,060/QALY gained, respec-
tively (Brisson et al. 2007b). Another study, conducted by
the Centers for Disease Control and Prevention (CDC) in
the USA estimated that vaccination of 12-year-old girls
with the quadrivalent (HPV 6/11/16/18) vaccine had a cost-
effectiveness ratio at least 30% lower than with the bivalent
(HPV 16/18) vaccine (Chesson et al. 2008).
To date, there has been limited use of economic analyses
for such decisions in Germany compared to some other
European countries such as the UK. However, this might
change with German insurance companies increasing their
focus on cost and forthcoming requirements for economic
analysis to be performed as part of the reviews of new
interventions by the German Health Technology Agency,
the Institute for Quality and Efficiency in Health Care,
which advises the Federal Ministry of Health. In addition,
84 J Public Health (2009) 17:77–86
the German Standing Committee on Vaccinations (STIKO)
at the Robert Koch Institute has recommended the
introduction of universal vaccination against HPV types
16 and 18 for all girls between the age of 12 and 17 in order
to reduce the incidence of cervical cancer in the population
(Robert Koch Institute 2007). Our analysis focussed on a
single cohort, but dynamic transmission models, which
allow seeing the impact of catch-up programmes, conclude
that an initial catch-up programme for girls aged up to 18 is
likely to be cost-effective (Dasbach et al. 2008; Jit et al.
2008). The STIKO statement includes an assessment of the
possible impact of an HPV vaccination programme in
Germany. For a 1996 birth cohort and assuming a lifetime
vaccination effectiveness rate of 92.5%, it was estimated
that the NNV to prevent one case of cervical cancer was 98.
These estimates are similar to the NNV of 120 estimated
from our model for Germany.
A policy issue that needs addressing in Germany is the
concern that the current policy of annual screening of >20-
year-old females is sub-optimal. A recent German study
demonstrated that cost-effectiveness could be improved
with screening intervals of 3–5 years, concluding that the
German cervical screening programme was in need of
reform (Bischoff-Everding et al. 2006). The effectiveness of
existing screening strategies could therefore constrain the
cost-effectiveness of screening plus vaccination pro-
grammes for HPV infection.
A further policy issue is that there is a risk of lower
adherence to cervical cancer screening with a universal
vaccination programme, which could be addressed via
education campaigns to advise young women of the
continued importance of attending cervical screening.
In conclusion, our analysis supports a national
programme of adding the HPV tetravalent vaccine in
adolescent females to the national cervical screening
programme in Germany as a cost-effective strategy from a
health care and public health perspective, due to the
significant impact it can have on reducing the burden of
disease associated with HPV-related diseases.
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